PYXS

Pyxis Oncology Inc

Add to Watchlist

Advanced Chart

1.190

-0.070(-5.560%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

1.300

Open

1.260

VWAP

1.24

Vol

460.11K

Mkt Cap

73.72M

Low

1.180

Amount

569.09K

EV/EBITDA(TTM)

Total Shares

58.89M

-48.78M

EV/OCF(TTM)

P/S(TTM)

4.56

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

-0.297

-15.24%

-0.297

+2.3%

-0.300

+400%

Estimates Revision

The market is revising No Change the revenue expectations for Pyxis Oncology, Inc. (PYXS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -19.05%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-9.19%

In Past 3 Month

Stock Price

Go Down

-19.05%

In Past 3 Month

7 Analyst Rating

509.24% Upside

Wall Street analysts forecast PYXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYXS is 7.25 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

509.24% Upside

Current: 1.190

Low

5.00

Averages

7.25

High

10.00

509.24% Upside

Current: 1.190

Low

5.00

Averages

7.25

High

10.00

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2025-03-19

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-03-19

Reiterates

Strong Buy

Reason

RBC Capital

Leonid Timashev

Buy

Reiterates

2025-03-19

Reason

RBC Capital

Leonid Timashev

Price Target

2025-03-19

Reiterates

Buy

Reason

RBC Capital

Leonid Timashev

Buy

Reiterates

$10 → $8

2024-12-20

Reason

RBC Capital

Leonid Timashev

Price Target

$10 → $8

2024-12-20

Reiterates

Buy

Reason

RBC Capital analyst Leonid Timashev lowered the firm's price target on Pyxis Oncology to $8 from $10 and keeps an Outperform rating on the shares. The company's pipeline update to prioritize PYX-201 over further investment in PYX-106 is "prudent" given the early signs of activity and the operating expense savings that will be leveraged to continue to advance PYX-201 development, though the firm is reducing its price target on lower "pipeline optionality", the analyst tells investors in a research note.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$7 → $5

2024-12-20

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$7 → $5

2024-12-20

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2024-11-21

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2024-11-21

Reiterates

Strong Buy

Reason

William Blair

Andy Hsieh

Buy

Hold

Downgrades

n/a

2024-11-21

Reason

William Blair

Andy Hsieh

Price Target

n/a

2024-11-21

Downgrades

Buy

Hold

Reason

William Blair analyst Andy Hsieh downgraded Pyxis Oncology to Market Perform from Outperform.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pyxis Oncology Inc (PYXS.O) is -0.99, compared to its 5-year average forward P/E of -1.97. For a more detailed relative valuation and DCF analysis to assess Pyxis Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.97

Current PE

-0.99

Overvalued PE

-0.33

Undervalued PE

-3.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.20

Current EV/EBITDA

0.22

Overvalued EV/EBITDA

1.51

Undervalued EV/EBITDA

-1.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

78.70

Current PS

0.00

Overvalued PS

239.48

Undervalued PS

-82.08

Financials

Annual

Quarterly

FY2024Q4

0.00

Total Revenue

FY2024Q4

YoY :

+7.53%

-19.11M

Operating Profit

FY2024Q4

YoY :

+128.06%

-35.57M

Net Income after Tax

FY2024Q4

YoY :

+65.71%

-0.58

EPS - Diluted

FY2024Q4

YoY :

+26.46%

-19.29M

Free Cash Flow

FY2024Q4

97.06

Gross Profit Margin - %

FY2024Q4

-358.66

FCF Margin - %

FY2024Q4

-478.95

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

174.4K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

320.0K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.1M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

174.4K

USD

Months

0-12

0.0

USD

Months

PYXS News & Events

Events Timeline

2025-03-18 (ET)

2025-03-18

07:32:31

Pyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)

2025-02-26 (ET)

2025-02-26

07:34:31

Pyxis Oncology granted Fast Track designation for PYX-201 monotherapy

2024-12-19 (ET)

2024-12-19

15:17:10

Pyxis Oncology to prioritize PYX-201, suspends investment in PYX-106

News

1.0

04-02Newsfilter

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

9.0

03-25Newsfilter

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

4.0

03-19Business Insider

RBC Capital Remains a Buy on Pyxis Oncology (PYXS)

People Also Watch

Compass Therapeutics Inc.

M3-Brigade Acquisition V Corp

Oil States International Inc

Community West Bancshares

Bridgewater Bancshares Inc

15.820

USD

+0.57%

FAQ

What is Pyxis Oncology Inc (PYXS) stock price today?

The current price of PYXS is 1.19 USD — it has decreased -5.56 % in the last trading day.

PYXS

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

PYXS News & Events

Events Timeline

News

People Also Watch

FAQ

What is Pyxis Oncology Inc (PYXS) stock price today?

What is Pyxis Oncology Inc (PYXS)'s business?

What is the price predicton of PYXS Stock?

What is Pyxis Oncology Inc (PYXS)'s revenue for the last quarter?

What is Pyxis Oncology Inc (PYXS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Pyxis Oncology Inc (PYXS)'s fundamentals?

How many employees does Pyxis Oncology Inc (PYXS). have?

What is Pyxis Oncology Inc (PYXS) market cap?